Immunovia Announces Company On Track with Commercial Test Model Study
LUND, SWEDEN ― Immunovia AB (publ) (“Immunovia”) today announced that the Commercial Test Model Study for Immunovia’s IMMray™ PanCan-d, a blood-based test for early diagnosis of pancreatic cancer, is on track. Following the excellent results from Immunovia’s Optimization Study for IMMray™ PanCan-d, the steps to market remain the same and includes the Commercial Test Model Study, now in full force, followed by the final Verification and Validation studies, after which the sales will commence in Q3 2020.
Additionally, Immunovia reports that the company has already obtained all the fresh, high-quality samples needed for this step. As previously announced, the Commercial Test Model Study will use up to 1200 fresh blood samples in order to fine tune the algorithms used in IMMray™ PanCan-d and further test the signature of IMMray™ PanCan-d. The company has collected fresh blood samples from 5 sites from USA and Europe, which adds to both sample and site diversit and matches the commercial clinical situation.
The Commercial Test Model Study process for IMMray™ PanCan-d will be completed on-time by year end as previously communicated.
“Immunovia is right on track on this next step and all preparations for our planned launch in Q3 2020 are in place,” commented Mats Grahn, CEO. “We, at Immunovia, remain fully committed and focused on the commercialization of IMMray™ PanCan-d and continue to maximize efficiency while maintaining our high quality and on-time delivery.”
For more information, please contact:
Julie Silber, Director of Investor Relations, Immunovia
Tel: +46 7 93 486 277
This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:30 (CET) on September 30, 2019.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.